Oncocytoma on renal mass biopsy: is it still the same histology when surgery is performed? Results from UroCCR-104 study.
Active surveillance
Oncocytoma
Partial nephrectomy
Renal mass
Renal mass biopsy
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
11
05
2022
accepted:
08
12
2022
pubmed:
13
1
2023
medline:
25
2
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
To describe clinical features of patients with oncocytoma on renal biopsy (RMB), correlation with final histology on surgically treated patients, and predictive factors of discrepancy between RMB and final histology. This was a retrospective study conducted in the framework of the UroCCR project (NCT03293563). All tumors with oncocytoma on RMB were selected and all pathological reports were reviewed. Patients with the RMB simultaneously performed with a focal treatment, synchronous bilateral tumors and ambiguous RMB report were excluded. Discrepancy between RMB and definitive histology was evaluated using a uni- and multivariable logistic regression analyses model. Overall, 119 tumors with oncocytoma on RMB, from 15 centers, were included. Of those, 54 (45.4%) had upfront surgery and 65 (54.6%) had active surveillance (AS). In renal masses with initial active surveillance, with a median follow-up of 28 months, 23 (19.3%) underwent surgery, 4 (3.4%) received focal treatment and 38 (31.9%) remained on AS. On final pathology, only 51 of the 75 surgically treated tumors (68.0%) had oncocytoma, while 24 presented malignant tumors (mainly chromophobe carcinoma (19.2%), and hybrid oncocytic/chromophobe tumor (HOCT) (6.8%)) leading to a discrepancy of 32.0% between RMB and final pathology. The only predictive factor of a discrepancy between RMB and definitive histology was a biopsy done outside of the center (Odds ratio: 3.22 [95%-confidence interval: 1.08-9.61], p = 0.03). Despite the increase of RMB in more and more centers, histologic discrepancy between RMB and definitive histology remains significant. This information should be discussed with patients and taken into consideration before treatment decision.
Identifiants
pubmed: 36633650
doi: 10.1007/s00345-022-04261-3
pii: 10.1007/s00345-022-04261-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
483-489Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Richard PO, Lavallée LT, Pouliot F, Komisarenko M, Martin L, Lattouf JB et al (2018) Is routine renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses? J Urol 200(4):731–736
doi: 10.1016/j.juro.2018.04.015
pubmed: 29653161
Kim JH, Li S, Khandwala Y, Chung KJ, Park HK, Chung BI (2019) Association of prevalence of benign pathologic findings after partial nephrectomy with preoperative imaging patterns in the United States from 2007 to 2014. JAMA Surg 154(3):225–231
doi: 10.1001/jamasurg.2018.4602
pubmed: 30516801
Schlomer B, Figenshau RS, Yan Y, Venkatesh R, Bhayani SB (2006) Pathological features of renal neoplasms classified by size and symptomatology. J Urol 176(4):1317–1320
doi: 10.1016/j.juro.2006.06.005
pubmed: 16952619
Garstka N, Shariat SF, Remzi M (2018) The evolving role of percutaneous biopsy in renal masses. Curr Opin Urol 28(4):364–368
doi: 10.1097/MOU.0000000000000513
pubmed: 29847524
Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J et al (2016) Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 69(4):660–673
doi: 10.1016/j.eururo.2015.07.072
pubmed: 26323946
Filippiadis D, Mauri G, Marra P, Charalampopoulos G, Gennaro N, De Cobelli F (2019) Percutaneous ablation techniques for renal cell carcinoma: current status and future trends. Int J Hyperthermia 36(2):21–30
doi: 10.1080/02656736.2019.1647352
pubmed: 31537160
Mir MC, Capitanio U, Bertolo R, Ouzaid I, Salagierski M, Kriegmair M et al (2018) Role of active surveillance for localized small renal masses. Eur Urol Oncol 1(3):177–187
doi: 10.1016/j.euo.2018.05.001
pubmed: 31102618
Ozambela M, Wang Y, Leow JJ, Silverman SG, Chung BI, Chang SL (2020) Contemporary trends in percutaneous renal mass biopsy utilization in the United States. Urol Oncol Semin Orig Investig. 38(11):835–843
Kutikov A, Smaldone MC, Uzzo RG, Haifler M, Bratslavsky G, Leibovich BC (2016) Renal mass biopsy: always, sometimes, or never? Eur Urol 70(3):403–406
doi: 10.1016/j.eururo.2016.04.001
pubmed: 27085625
Tsivian M, Rampersaud EN, del Pilar LM, Joniau S, Leveillee RJ, Shingleton WB et al (2014) Small renal mass biopsy–how, what and when: report from an international consensus panel. BJU Int 113(6):854–863
doi: 10.1111/bju.12470
pubmed: 24119037
Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB et al (2021) Updated European Association of urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. Eur Urol 79(3):339–342
doi: 10.1016/j.eururo.2020.12.005
pubmed: 33357997
Deledalle FX, Ambrosetti D, Durand M, Michel F, Baboudjian M, Gondran-Tellier B et al (2021) Active surveillance for biopsy proven renal oncocytomas: outcomes and feasibility. Urology 156:185–190
doi: 10.1016/j.urology.2021.05.034
pubmed: 34087310
Neves JB, Varley R, Agnesi S, Withington J, Rodrigues FB, Warren H et al (2021) Growth and renal function dynamics of renal oncocytomas in patients on active surveillance. BJU Int 128(6):722–727
doi: 10.1111/bju.15499
pubmed: 34046981
Richard PO, Jewett MA, Bhatt JR, Evans AJ, Timilsina N, Finelli A (2016) Active surveillance for renal neoplasms with oncocytic features is safe. J Urol 195(3):581–587
doi: 10.1016/j.juro.2015.09.067
pubmed: 26388501
Mikami S, Kuroda N, Nagashima Y, Ohe C, Hayashi H, Mizuno R et al (2019) Classification of solid renal tumor with oncocytic/eosinophilic cytoplasm: is hybrid oncocytic/chromophobe renal tumor a subtype of oncocytoma, chromophobe renal cell carcinoma, or a distinct tumor entity? Ann Transl Med 7(Suppl 8):2
Patel HD, Druskin SC, Rowe SP, Pierorazio PM, Gorin MA, Allaf ME (2017) Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int 119(5):661–666
doi: 10.1111/bju.13763
pubmed: 28058773
Warren H, Neves JB, Tran MGB (2021) Renal oncocytoma: landscape of diagnosis and management. BJU Int 128(6):685–687
doi: 10.1111/bju.15496
pubmed: 34036709
Alderman MA, Daignault S, Wolf JS, Palapattu GS, Weizer AZ, Hafez KS et al (2016) Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up. Hum Pathol 55:1–10
doi: 10.1016/j.humpath.2016.03.017
pubmed: 27085554
Ng KL, Rajandram R, Morais C, Yap NY, Samaratunga H, Gobe GC et al (2014) Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem? J Clin Pathol 67(2):97–104
doi: 10.1136/jclinpath-2013-201895
pubmed: 24170213
Abdessater M, Kanbar A, Comperat E, Dupont-Athenor A, Alechinsky L, Mouton M et al (2020) Renal oncocytoma: an algorithm for diagnosis and management. Urology 143:173–180
doi: 10.1016/j.urology.2020.05.047
pubmed: 32512107
Ma LX, Craig KM, Mosquera JM, Robinson BD, Scherr DS, Pizzo JD et al (2020) Contemporary results and clinical utility of renal mass biopsies in the setting of ablative therapy: a single center experience. Cancer Treat Res Commun 25:100209
doi: 10.1016/j.ctarc.2020.100209
pubmed: 32979705
Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A et al (2022) The 2022 world health organization classification of tumours of the urinary system and male genital organs—part a: renal, penile, and testicular tumours. Eur Urol 82(5):458–468
doi: 10.1016/j.eururo.2022.06.016
pubmed: 35853783
Liu S, Lee S, Rashid P, Bangash H, Hamid A, Lau J et al (2016) Active surveillance is suitable for intermediate term follow-up of renal oncocytoma diagnosed by percutaneous core biopsy. BJU Int 118:30–34
doi: 10.1111/bju.13538
pubmed: 27457972
Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C et al (2021) Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival. JAMA Netw Open 4(1):2021869
doi: 10.1001/jamanetworkopen.2020.21869
Neves JB, Withington J, Fowler S, Patki P, Barod R, Mumtaz F et al (2018) Contemporary surgical management of renal oncocytoma: a nation’s outcome. BJU Int 121(6):893–899
doi: 10.1111/bju.14159
pubmed: 29397002
Kawaguchi S, Fernandes KA, Finelli A, Robinette M, Fleshner N, Jewett MAS (2011) Most renal oncocytomas appear to grow: observations of tumor kinetics with active surveillance. J Urol 186(4):1218–1222
doi: 10.1016/j.juro.2011.05.080
pubmed: 21849182
Galmiche C, Bernhard JC, Yacoub M, Ravaud A, Grenier N, Cornelis F (2017) Is multiparametric MRI useful for differentiating oncocytomas from chromophobe renal cell carcinomas? Am J Roentgenol 208(2):343–350
doi: 10.2214/AJR.16.16832
Wilson MP, Katlariwala P, Murad MH, Abele J, McInnes MD, Low G (2020) Diagnostic accuracy of 99mTc-sestamibi SPECT/CT for detecting renal oncocytomas and other benign renal lesions: a systematic review and meta-analysis. Abdom Radiol 45:8
doi: 10.1007/s00261-020-02469-8
Li X, Ma Q, Nie P, Zheng Y, Dong C, Xu W (2022) A CT-based radiomics nomogram for differentiation of renal oncocytoma and chromophobe renal cell carcinoma with a central scar-matched study. Br J Radiol 95(1129):20210534
doi: 10.1259/bjr.20210534
pubmed: 34735296
Trpkov K, Williamson SR, Gao Y, Martinek P, Cheng L, Sangoi AR et al (2019) Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology 75(2):174–184
doi: 10.1111/his.13865
pubmed: 30895640